Literature DB >> 14967443

Ionizing radiation inhibition of distant untreated tumors (abscopal effect) is immune mediated.

Sandra Demaria1, Bruce Ng, Mary Louise Devitt, James S Babb, Noriko Kawashima, Leonard Liebes, Silvia C Formenti.   

Abstract

PURPOSE: Ionizing radiation can reduce tumor growth outside the field of radiation, known as the abscopal effect. Although it has been reported in multiple malignancies, the abscopal effect remains a rare and poorly understood event. Ionizing radiation generates inflammatory signals and, in principle, could provide both tumor-specific antigens from dying cells and maturation stimuli that are necessary for dendritic cells' activation of tumor-specific T cells. We therefore tested the hypothesis that the abscopal effect elicited by radiation is immune mediated. This was directly tested by enhancing the number of available dendritic cells using the growth factor Flt3-Ligand (Flt3-L). METHODS AND MATERIALS: Mice bearing a syngeneic mammary carcinoma, 67NR, in both flanks were treated with Flt3-L daily for 10 days after local radiation therapy (RT) to only 1 of the 2 tumors at a single dose of 2 or 6 Gy. The second nonirradiated tumor was used as indicator of the abscopal effect. Data were analyzed using repeated measures regression.
RESULTS: RT alone led to growth delay exclusively of the irradiated 67NR tumor, as expected. Surprisingly, growth of the nonirradiated tumor was also impaired by the combination of RT and Flt3-L. As control, Flt3-L had no effect without RT. Importantly, the abscopal effect was shown to be tumor specific, because growth of a nonirradiated A20 lymphoma in the same mice containing a treated 67NR tumor was not affected. Moreover, no growth delay of nonirradiated 67NR tumors was observed when T cell deficient (nude) mice were treated with RT plus Flt3-L.
CONCLUSIONS: These results demonstrate that the abscopal effect is in part immune mediated and that T cells are required to mediate distant tumor inhibition induced by radiation.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 14967443     DOI: 10.1016/j.ijrobp.2003.09.012

Source DB:  PubMed          Journal:  Int J Radiat Oncol Biol Phys        ISSN: 0360-3016            Impact factor:   7.038


  452 in total

1.  Stereotactic radiosurgery for melanoma brain metastases in patients receiving ipilimumab: safety profile and efficacy of combined treatment.

Authors:  Ana P Kiess; Jedd D Wolchok; Christopher A Barker; Michael A Postow; Viviane Tabar; Jason T Huse; Timothy A Chan; Yoshiya Yamada; Kathryn Beal
Journal:  Int J Radiat Oncol Biol Phys       Date:  2015-03-05       Impact factor: 7.038

Review 2.  In situ vaccination with nanoparticles for cancer immunotherapy: understanding the immunology.

Authors:  Chenkai Mao; Michael-Joseph Gorbet; Akansha Singh; Ashish Ranjan; Steven Fiering
Journal:  Int J Hyperthermia       Date:  2020-12       Impact factor: 3.914

Review 3.  The abscopal effect of local radiotherapy: using immunotherapy to make a rare event clinically relevant.

Authors:  Kobe Reynders; Tim Illidge; Shankar Siva; Joe Y Chang; Dirk De Ruysscher
Journal:  Cancer Treat Rev       Date:  2015-03-28       Impact factor: 12.111

4.  Abscopal regression of antigen disparate tumors by antigen cascade after systemic tumor vaccination in combination with local tumor radiation.

Authors:  James W Hodge; Hadley J Sharp; Sofia R Gameiro
Journal:  Cancer Biother Radiopharm       Date:  2012-01-27       Impact factor: 3.099

Review 5.  Stereotactic body radiotherapy for oligo-recurrence within the nodal area from colorectal cancer.

Authors:  Young Seok Seo; Mi-Sook Kim; Hyung-Jun Yoo; Won-Il Jang
Journal:  World J Gastroenterol       Date:  2014-02-28       Impact factor: 5.742

6.  Tumour radiosensitivity is associated with immune activation in solid tumours.

Authors:  Tobin Strom; Louis B Harrison; Anna R Giuliano; Michael J Schell; Steven A Eschrich; Anders Berglund; William Fulp; Ram Thapa; Domenico Coppola; Sungjune Kim; Jessica Frakes; John Foekens; James J Mulé; Javier F Torres-Roca
Journal:  Eur J Cancer       Date:  2017-08-29       Impact factor: 9.162

7.  Harnessing the Immunomodulatory Effects of Radiation in Urinary Bladder Cancer.

Authors:  Waseem Abbas; Vineeta Goel; Arun Verma; Vineet G Gupta; Ranga R Rao
Journal:  Cureus       Date:  2019-02-20

8.  Activity and safety of radiotherapy with anti-PD-1 drug therapy in patients with metastatic melanoma.

Authors:  E Liniker; A M Menzies; B Y Kong; A Cooper; S Ramanujam; S Lo; R F Kefford; G B Fogarty; A Guminski; T W Wang; M S Carlino; A Hong; G V Long
Journal:  Oncoimmunology       Date:  2016-08-19       Impact factor: 8.110

Review 9.  Combining brachytherapy and immunotherapy to achieve in situ tumor vaccination: A review of cooperative mechanisms and clinical opportunities.

Authors:  Ravi B Patel; Claire C Baniel; Raghava N Sriramaneni; Kristin Bradley; Stephanie Markovina; Zachary S Morris
Journal:  Brachytherapy       Date:  2018-08-02       Impact factor: 2.362

Review 10.  Current clinical trials testing combinations of immunotherapy and radiation.

Authors:  Marka Crittenden; Holbrook Kohrt; Ronald Levy; Jennifer Jones; Kevin Camphausen; Adam Dicker; Sandra Demaria; Silvia Formenti
Journal:  Semin Radiat Oncol       Date:  2015-01       Impact factor: 5.934

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.